Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
Rhea-AI Summary
Propanc Biopharma (NASDAQ:PPCB) filed a new provisional patent application with IP Australia on January 20, 2026 for methods to produce fully synthetic recombinant trypsinogen and chymotrypsinogen (Rec-PRP).
The filing describes an optimized yeast-based expression system to manufacture a world-first fully synthetic version of PRP intended as a long-term therapy to treat and prevent metastatic cancer from solid tumors. Management says Rec-PRP could enable long shelf life without refrigeration, scalable lot-consistent supply without animal sourcing, and improved global distribution. The release cites a projected global metastatic cancer market of $111 billion by 2027 and frames the provisional as the third filing in two months to expand the company IP portfolio ahead of national phase filings worldwide.
Positive
- Provisional patent filed with IP Australia strengthening IP portfolio
- Rec-PRP aims for refrigeration-free stability, aiding global distribution
- Scalable, animal-free production could reduce lot-to-lot variation
- Market reference: metastatic cancer market projected at $111B by 2027
Negative
- Provisional status: application filed is provisional and not yet granted
News Market Reaction – PPCB
On the day this news was published, PPCB declined 4.69%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.4% during that session. Argus tracked a trough of -29.7% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $206K from the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 6.8x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PPCB was down 10.76% with elevated volume while peers were mixed: RNTX up 5.22%, AKTX and ALLR modestly positive, LIXT and BOLD negative. Momentum scanner showed CRIS down 6.54% and RNTX up 4.13%, indicating stock-specific rather than broad sector pressure.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Pipeline update | Positive | -17.1% | Outlined PRP preclinical data, orphan status, funding context, and 2026 trial plans. |
| Jan 13 | Shareholder update | Positive | -4.3% | Provided 2025–2026 roadmap, funding raised, IP scale, and Rec‑PRP backup work. |
| Dec 22 | Clinical research | Positive | -8.4% | Published PRP proenzyme effects on PDAC fibroblasts and planned Phase 1b trial. |
| Dec 04 | Research collaboration | Positive | -4.3% | Announced mesenchymal drift program and PRP-based fibrosis patent application. |
| Dec 01 | Patent filing step | Positive | +5.5% | Sought foreign filing license in Spain for resistant cancer and fibrosis patents. |
Recent positive R&D and corporate updates have often been followed by negative one-day price reactions, suggesting a pattern of weakness into good news.
Over the past few months, Propanc has highlighted progress around its lead candidate PRP and backup Rec‑PRP, including preclinical pancreatic cancer data, fibroblast research in PDAC, and preparations for a Phase 1b study planned for 2026. Shareholder updates noted the company remains pre‑revenue but raised about $4M after its Nasdaq uplisting and has invested over $30M historically. Multiple patent-related announcements and fibrosis expansion efforts have not prevented several double‑digit single‑day declines, framing today’s new provisional patent in a context of persistent market skepticism.
Market Pulse Summary
This announcement added a new provisional patent application with IP Australia, supporting a fully synthetic recombinant version of PRP (Rec‑PRP) and marking the third such filing in two months. It reinforces Propanc’s strategy to build a platform technology for metastatic cancer and other indications. In light of prior updates about Phase 1b plans, significant accumulated losses, and Nasdaq compliance timelines, investors may watch how this IP step translates into funding, partnerships, and clinical progress over 2026–2027.
Key Terms
provisional patent application regulatory
recombinant medical
metastatic cancer medical
in vivo medical
expression system technical
proenzymes medical
AI-generated analysis. Not financial advice.
A World-First, Fully Synthetic Recombinant Version of PRP
MELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a new provisional patent application has been filed for methods of producing trypinsogen and chymotrypsinogen with IP Australia. The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP, a long-term therapy for the treatment and prevention of metastatic cancer from solid tumors. According to Emergen Research, the global metastatic cancer market is projected to be worth
A fully synthetic version of trypsinogen and chymotrypsinogen, called Rec-PRP, could have additional benefits to a global healthcare system that further capitalizes on a new therapeutic approach to treating cancer. For example, both proenzymes are synthesized by an in vivo (living organism) expression system, such as yeast cells, to produce proteins that could be maintained for long periods of time without suffering degradation in the absence of refrigeration. This is useful for a longer self-life as well as global distribution, particularly in warmer climates and developing regions where refrigeration is not available. Further, the program could produce large quantities of trypsinogen and chymotrypsinogen for commercial use that exhibits minimal variation between lots and without sourcing from animals. Therefore, management believes a fully synthetic recombinant version of PRP would have tremendous implications from a regulatory perspective, but also a practical, commercial benefit for global distribution.
“This provisional patent application is the third one filed over the past two months and will enhance our IP portfolio significantly as we enter national phase in countries worldwide for each of these patent applications,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We continue to execute our strategic plan building a platform technology that could be a world-first therapeutic approach to metastatic cancer from solid tumors, but without severe or serious side effects associated with standard treatments. Further, we are expanding our research into other therapeutic indications where there is a significant unmet medical need. We are building a strong and stable future for our Company and shareholders over the long term.”
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
What did Propanc (PPCB) announce on January 20, 2026 about Rec-PRP?
How could Propanc's Rec-PRP production method affect global distribution for PPCB therapies?
Does the January 20, 2026 Propanc patent filing mean Rec-PRP is approved for clinical use?
How does the Propanc announcement impact PPCB's intellectual property position?
What commercial benefits does Propanc claim for Rec-PRP in the January 20, 2026 release?
What market size did Propanc cite in its January 20, 2026 announcement related to metastatic cancer?
